Using the industry peer median P/E Multiples multiple (trailing + forward), TransMedics Group, Inc. (TMDX) has a fair value of $69.76 based on 2 comparable companies in the Medical - Devices industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| TransMedics Group, Inc.TMDX | 2,607 | 13.2x | 24.7x |
| Option Care Health, Inc. | 4,402 | 21.7x | 14.9x |
| Indivior Pharmaceuticals Inc | 3,796 | 18.5x | 9.7x |
| Industry Median | 20.1x | 12.3x | |
| (*) Profit after tax | 190 | 105 | |
| Equity Value | 3,826 | 1,830 | |
| (/) Outstanding shares | 41 | 41 | |
| Fair Price | $94 | $45 | |
Using the industry peer median EV/EBITDA multiple (trailing + forward), TransMedics Group, Inc. (TMDX) has a fair value of $49.50 based on 3 comparable companies in the Medical - Devices industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| TransMedics Group, Inc.TMDX | 2,607 | 17.4x | 17.6x |
| Bruker Corporation | 5,593 | 25.5x | 24.5x |
| Option Care Health, Inc. | 4,402 | 8.8x | 8.4x |
| Indivior Pharmaceuticals Inc | 3,796 | 13.0x | 13.9x |
| Industry Median | 13.0x | 13.9x | |
| (*) EBITDA | 148 | 147 | |
| = Enterprise Value | 1,930 | 2,046 | |
| (-) Net Debt | -19 | -19 | |
| Equity Value | 1,949 | 2,065 | |
| (/) Outstanding shares | 41 | 41 | |
| Fair Price | $48 | $51 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), TransMedics Group, Inc. (TMDX) has a fair value of $57.84 based on 8 comparable companies in the Medical - Devices industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| TransMedics Group, Inc.TMDX | 2,607 | 4.3x | 4.3x |
| Kymera Therapeutics, Inc. | 6,962 | 170.6x | 168.8x |
| Glaukos Corporation | 6,777 | 13.5x | 11.1x |
| Bruker Corporation | 5,593 | 2.1x | 2.0x |
| Option Care Health, Inc. | 4,402 | 0.7x | 0.7x |
| NewAmsterdam Pharma Company N.V. | 3,923 | 152.6x | 134.0x |
| Indivior Pharmaceuticals Inc | 3,796 | 3.2x | 3.4x |
| Oscar Health, Inc. | 3,308 | 0.1x | 0.1x |
| Hinge Health, Inc. | 3,087 | 4.9x | 3.9x |
| Industry Median | 4.0x | 3.7x | |
| (*) Revenue | 605 | 601 | |
| = Enterprise Value | 2,452 | 2,201 | |
| (-) Net Debt | -19 | -19 | |
| Equity Value | 2,471 | 2,219 | |
| (/) Outstanding shares | 41 | 41 | |
| Fair Price | $61 | $55 | |
Using the PEG framework with analyst consensus forward EPS growth of 8.0%, the company has a fair value of $19.99 based on NTM EPS (FY2026) of $2.50.
| EPS Growth RateForward | -0.0% |
| Adjusted Growth (clamped 8–25%)Clamped | 8.0% |
| Fair P/E | 8.0x |
| NTM EPS (FY2026) | $2.50 |
| Fair Value | $19.99 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $4.87 | — | — |
| FY2026E | $2.50 | -48.7% | 9 |
| FY2027E | $3.68 | +47.1% | 9 |
| FY2028E | $4.87 | +32.4% | 5 |
3Y Forward EPS CAGR: -0.0%
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $-44.2M | $-1.60 | — |
| FY2022 | $-36.2M | $-1.23 | — |
| FY2023 | $-25.0M | $-0.77 | — |
| FY2024 | $35.5M | $1.01 | — |
| FY2025 | $190.3M | $4.87 | +382.2% |
4Y Historical EPS CAGR: 382.2%
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.